Icar30 T Cells
Anaplastic Large Cell Lymphoma
Immune Cell, Inc.Cell therapyPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
52 Active assets in the Anaplastic Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Seagen Inc. | Phase 4 | BBB |
Crizotinib Pfizer | Phase 4 | BBB |
Inno-206 City of Hope Medical Center | Phase 4 | BBB |
Brentuximab Vedotin Seagen Inc. | Phase 3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Icar30 T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →